Google
NVCR — NOVOCURE LTD (Healthcare >> Medical Devices)
NVCR FAQ
What is NVCR's ROE?
NOVOCURE LTD reports a Return on Equity (ROE) of -52.32%.
What is NVCR's dividend yield?
NOVOCURE LTD offers a dividend yield of 0.00%.
What is NVCR's Deepscope Quality Score?
Deepscope rates NVCR's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NVCR?
Deepscope's AI Timing Score for NVCR is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NVCR belong to?
NOVOCURE LTD is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange.
|
USD 17.16
Price
-0.83
(-4.61%)
Day Change
|
|
|---|
NVCR, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 17.16 |
| PBV / Sector |
6.01 / 7.50
|
| Earning Per Share | -1.49 |
| PE / Sector |
N/A / 29.01
|
| PEG or PE/Growth / Sector |
N/A / 0.39
|
| Average 1M Daily Value |
26.95 M
GREAT
|
| Average 1W Daily Value |
30.19 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:05 |
| Symbol | NVCR |
| Name | NOVOCURE LTD |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 115.82 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,987.49 / 18,389.26 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Neuhofstrasse 21, Baar, Switzerland, 6340
Phone: 44 15 3475 6700
Website: https://www.novocure.com
Employees: 1,605
Sector: Healthcare >> Medical Devices
Description: NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
